医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Covance Recognized with Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award

2017年10月16日 PM09:45
このエントリーをはてなブックマークに追加


 

BURLINGTON, N.C.

LabCorp (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development business (Covance) has been awarded the 2017 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award. The award recognizes Covance’s relentless focus on delivering value to customers by offering drug development solutions that meet the unique opportunities and needs of the Asia-Pacific biopharmaceutical industry.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016005631/en/

Covance employees accept Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award (Photo: B ...

Covance employees accept Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award (Photo: Business Wire)

“This honor demonstrates that our commitment and focus on Asia Pacific is creating a distinctive advantage for our customers,” said John Ratliff, CEO of Covance. “We have continued to expand our drug development capabilities in Asia Pacific, from dedicated nonclinical and clinical testing laboratories to clinical trial operations, as well as unique regulatory and market access solutions. In doing so, we have developed both deep local knowledge and a track record of success of which we are very proud. I’d like to thank our Asia-Pacific team for their dedication to our customers and helping to advance our mission of improving health and improving lives around the world.”

Covance established its presence in Asia Pacific in 1988 and has continued to grow its comprehensive solutions in the region from research to real world, including non-clinical development, central laboratory services, clinical development and market access solutions. Combining its global infrastructure, data analytics and quality standards with local expertise and insight, Covance has successfully created a tailored and relevant offering for the Asia-Pacific market.

“Covance has a unique, integrated drug development portfolio with informatics capabilities that enables biopharma clients to reduce the cost of developing new drugs,” said Sanjeev Kumar, industry manager, Healthcare Practice, Frost & Sullivan. “With close to 30 years of experience in the Asian market, Covance serves a wide range of customers by utilizing its experience in study design, trial logistics, performance monitoring, clinical data management and analytics to deliver the best services to customers.”

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

This press release contains forward-looking statements about the Company’s future operations. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005631/en/

CONTACT

LabCorp
Media Contact:
Sue Maynard,
+1-336-436-8263
or
Investor Contact:
Scott
Frommer, +1-336-436-5076

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者